Myocardial Ischemia Market Report 2026

The myocardial ischemia market size has grown strongly in recent years. It will grow from $0.84 billion in 2025 to $0.9 billion in 2026 at a compound annual growth rate (CAGR) of 6.8%. The growth in the historic period can be attributed to rise in coronary artery disease cases, limited early screening programs, increasing prevalence of hypertension, dependence on traditional diagnostic methods, lifestyle-related risk factors.

The myocardial ischemia market size is expected to see strong growth in the next few years. It will grow to $1.14 billion in 2030 at a compound annual growth rate (CAGR) of 6.1%. The growth in the forecast period can be attributed to advancements in imaging technologies, growing adoption of precision medicine, expansion of preventive cardiology programs, increasing investment in cardiac r&d, rising demand for minimally invasive treatments. Major trends in the forecast period include growing adoption of advanced cardiac imaging technologies, rising preference for minimally invasive cardiac interventions, increasing use of combination drug therapies, greater focus on preventive cardiology and early risk screening, high demand for personalized cardiac treatment plans.

The rising incidence of diabetes is expected to propel the growth of the myocardial ischemia market going forward. Diabetes encompasses a group of metabolic disorders in which the body cannot produce or effectively use insulin, the hormone responsible for regulating blood sugar levels. The increasing prevalence of diabetes is driven by obesity, sedentary lifestyles, and genetic predisposition. This rise in diabetes contributes to a higher incidence of myocardial ischemia, fueling demand for diagnostic, therapeutic, and management solutions. For instance, in April 2023, according to The British Diabetic Association, a UK-based diabetes charity, 4.3 million people in the UK were diagnosed with diabetes, reflecting an increase of 148,951 cases compared to 2020-21. Additionally, over 2.4 million individuals in the UK are considered at high risk of developing type 2 diabetes. Therefore, the growing diabetes epidemic is driving the myocardial ischemia market.

Major companies in the myocardial ischemia market are focusing on developing innovative drugs, such as Lodoco (colchicine), to reduce cardiovascular inflammation and lower the risk of major cardiac events in patients with coronary artery disease. Lodoco is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and cardiovascular death in adults with established atherosclerotic disease or multiple cardiovascular risk factors. For example, in June 2023, Agepha Pharma, a US-based pharmaceutical company, launched Lodoco, which received FDA approval, marking the first treatment targeting cardiovascular inflammation. Data from the LoDoCo2 trial demonstrated a 31% relative reduction in cardiovascular events with 0.5 mg of colchicine once daily compared to placebo.

In March 2024, Novo Nordisk A/S, a Denmark-based pharmaceutical company, acquired Cardior Pharmaceuticals for €1.025 billion ($1.1 billion). This strategic acquisition allows Novo Nordisk to leverage Cardior’s expertise and ongoing clinical programs to accelerate the development of CDR132L and expand its portfolio of therapies in myocardial ischemia. Cardior Pharmaceuticals is a Germany-based biopharmaceutical company specializing in drugs for the treatment of myocardial ischemia.

Major companies operating in the myocardial ischemia market are Cardinal Health Inc., Pfizer Inc., Roche Holding AG, Bayer AG, Sanofi SA, Novartis AG, Bristol‑Myers Squibb Company, AstraZeneca Plc, Abbott Laboratories Inc., Eli Lilly and Company, Medtronic Plc, Boehringer Ingelheim International GmbH, Siemens Healthineers AG, Merck KGaA, GE HealthCare Technologies Inc., Fujifilm Holdings Corporation, Boston Scientific Corporation, Daiichi Sankyo Company Limited, Canon Medical Systems Corporation, Johnson & Johnson, Koninklijke Philips NV, Biotronik SE & Co KG, Edwards Lifesciences Corporation, Teva Pharmaceutical Industries Ltd, Schiller AG, AliveCor Inc.

North America was the largest region in the myocardial ischemia market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the myocardial ischemia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the myocardial ischemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs on imported cardiac diagnostic devices and interventional equipment have increased operational costs for hospitals and diagnostic centers, especially in regions with high reliance on foreign medical technology such as Asia-Pacific and Europe. These tariffs delay the procurement and adoption of advanced cardiac imaging and treatment systems. However, they also stimulate local manufacturing initiatives and encourage domestic innovation in producing cost-effective cardiac diagnostic tools.

The myocardial ischemia market research report is one of a series of new reports that provides myocardial ischemia market statistics, including myocardial ischemia industry global market size, regional shares, competitors with a myocardial ischemia market share, detailed myocardial ischemia market segments, market trends and opportunities, and any further data you may need to thrive in the myocardial ischemia industry. This myocardial ischemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Myocardial ischemia, also called cardiac ischemia, is a condition in which blood flow to the heart muscle is reduced, resulting in insufficient oxygen and nutrient supply to the heart and potential muscle damage. The most common cause is the buildup of plaque in the coronary arteries, which restricts blood flow.

The main types of myocardial ischemia are symptomatic and asymptomatic. Symptomatic myocardial ischemia occurs when an individual experiences symptoms such as chest pain or discomfort, commonly referred to as angina, during episodes of reduced blood flow. Diagnosis and treatment options are available and utilized by various end users, including hospitals, clinics, diagnostic centers, and ambulatory surgery centers.

The myocardial ischemia market consists of sales of statin, anticoagulants, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.